Table 5.
Selected Studies Utilizing Postoperative SBRT for Spine Metastases.a
| Author | Tumors, Pts | Histology (% Radioresistant) | Dose, Gy: GTV/CTV If Applicable | Follow-Up, months | Response | Survival |
|---|---|---|---|---|---|---|
| Tao et al 69 | 69 (66) | Mixed (≥85) | 16-24/1 or 27/3 or 30/5 | 30 (median) | 85% LC (1 year) | 74% (1 year, median 29 months) |
| Bate et al 38 | 21 | Mixed | Single fraction: 22 (median, range 16-22), hypofractionated: 20-30/2-5 | 13.7 | 90.5% (1 year) | NR |
| Laufer et al 71 | (186) | Mixed (77) | 18-36/5-6 or 24-30/3 or 24/1 | 7.6 (median) | 83.6% LC (1 year) >95% LC with SRS (1 year) | 26.3% PFS |
| Al-Omair et al 72 | (80) | Mixed (≥40) | 18-26/1 or 18-40/3-5 | 8.3 (median) | 84% LC (1 year) | 64% (1 year) |
| Massicotte et al 70 | 10 | Mixed (40) | 18-35/1-5 | 13 (median) | 70% LC | 80% OS |
| Rock et al 73 | 18 | Mixed (including primary) | 11.4/1 (mean) | 7 (median) | 92% neurological stability or improvement | NR |
| Gerszten et al 74 | 26 (26) | Mixed (≥15) | 16-20/1 | 16 (median) | 92% pain improvement | NR |
Abbreviations: CTV, clinical target volume; GTV, gross tumor volume; LC, local control; NR, not reported; OS, overall survival; PFS, progression-free survival; pts, patients; SBRT, stereotactic body radiation therapy; SRS, stereotactic radiosurgery.
a Radioresistant indicates renal, thyroid, hepatocellular, colon, non-small cell lung carcinoma, sarcoma, and melanoma or as defined by study authors.